Abstract
This phase I trial studies the side effects and best dose of nanoparticle albumin-bound
rapamycin when given together with temozolomide and irinotecan hydrochloride in treating
pediatric patients with solid tumors that have come back after treatment and a period of time
during which the tumor could not be detected or has not responded to treatment. Nanoparticle
albumin-bound rapamycin may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Chemotherapy drugs, such as temozolomide and irinotecan
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
nanoparticle albumin-bound rapamycin, temozolomide, and irinotecan hydrochloride may cause
the cancer to stop growing or shrink for a period of time and may lessen the symptoms that
are caused by the cancer.
